145020.KQ
Hugel, Inc.
KOE · Healthcare · Biotechnology · KR
KRW 240,500.00
−2.04%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 479.6B | 425.1B | 373.0B | 319.7B | 281.7B |
| Cost of Revenue | 113.6B | 102.1B | 85.9B | 73.5B | 62.8B |
| Gross Profit | 366.0B | 323.0B | 287.2B | 246.2B | 218.9B |
| Operating Expenses | |||||
| R&D Expense | 9.9B | 11.6B | 9.2B | 11.0B | 15.1B |
| SG&A Expense | 54.7B | 63.9B | 60.1B | 109.5B | 58.9B |
| General & Admin Expense | 4.7B | 5.4B | 5.8B | 6.7B | 5.3B |
| Selling & Marketing Expense | 50.0B | 58.4B | 54.3B | 61.2B | 53.6B |
| Other Expenses | 92.5B | 47.0B | 51.6B | 49.5B | 43.5B |
| Total Operating Expenses | 157.1B | 122.5B | 120.9B | 120.5B | 117.5B |
| Cost and Expenses | 270.7B | 223.5B | 206.8B | 194.0B | 180.3B |
| Operating Income (EBIT) | 208.9B | 200.5B | 166.2B | 125.7B | 101.4B |
| Non-Operating | |||||
| Interest Income | 13.6B | 12.6B | 14.7B | 14.7B | 11.5B |
| Interest Expense | 1.1B | 1.1B | 1.2B | 2.9B | 3.1B |
| Net Interest Income | 12.6B | 11.5B | 13.6B | 14.7B | 8.4B |
| Other Non-Op Income/Expense | 11.1B | (3.8B) | (1.0B) | 7.6B | (28.3B) |
| Non-Operating Income (excl Interest) | 3.0B | — | (128.9M) | 7.9B | 25.2B |
| EBT (Pre-Tax Income) | 220.0B | 197.5B | 165.2B | 133.3B | 73.1B |
| Income Tax Expense | 56.7B | 49.8B | 22.0B | 35.6B | 9.2B |
| Bottom Line | |||||
| Net Income | 158.0B | 140.9B | 135.8B | 93.1B | 57.3B |
| Earnings from Cont. Ops | 163.2B | 147.0B | 143.1B | 97.7B | 63.9B |
| Earnings from Discont. Ops | — | — | — | — | (3.2B) |
| Bottom Line Net Income | 158.1B | 141.5B | 135.8B | 93.1B | 57.3B |
| Per Share | |||||
| Basic EPS | ₩13,860 | ₩13,061 | ₩12,520 | ₩8,217 | ₩4,811 |
| Diluted EPS | ₩13,260 | ₩12,820 | ₩12,042 | ₩7,934 | ₩4,743 |
| Revenue Per Share | ₩37,759 | ₩33,111 | ₩33,975 | ₩28,225 | ₩23,636 |
| Shares | |||||
| Basic Shares Outstanding | 12.7M | 12.8M | 11.0M | 11.3M | 11.9M |
| Diluted Shares Outstanding | 12.7M | 12.8M | 11.3M | 11.7M | 12.1M |
| Profitability Metrics | |||||
| EBITDA | 200.0B | 220.3B | 181.4B | 131.6B | 115.4B |
| D&A | 21.1B | 19.7B | 15.0B | 13.9B | 14.0B |
| EBIT | 178.9B | 200.5B | 166.4B | 117.7B | 101.4B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026